Noble Financial Reaffirms Their Buy Rating on Baudax Bio (BXRX)

In a report released today, Gregory Aurand from Noble Financial maintained a Buy rating on Baudax Bio (BXRXResearch Report), with a price target of $0.60. The company’s shares closed yesterday at $0.14.

Aurand covers the Healthcare sector, focusing on stocks such as Baudax Bio, ChitogenX, and BioSig Technologies. According to TipRanks, Aurand has an average return of -60.9% and a 17.65% success rate on recommended stocks.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Baudax Bio with a $0.60 average price target.

See Insiders’ Hot Stocks on TipRanks >>

The company has a one-year high of $18.86 and a one-year low of $0.13. Currently, Baudax Bio has an average volume of 1.91M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Baudax Bio, Inc. is a pharmaceutical company focusing on developing and commercializing products for acute care settings. The company was founded in 2015 and is headquartered in Malvern, PA.

Read More on BXRX:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More